ASCO 2016 | Trial of durvalumab for bladder cancer

Thomas Powles

Thomas Powles, MD, PhD from Barts Cancer Institute, London, UK discusses key points of a new Phase III clinical trial looking at moving immune single agent and immune combination therapy into the frontline setting in bladder cancer (NCT02516241). The trial has three arms: chemotherapy vs. single agent durvalumab vs. a combination of durvalumab and tremelimumab. The hope is that chemotherapy can be replaced. Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter